Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Cyclophosphamide + Fludarabine + TAC01-HER2|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Cyclophosphamide||Cytoxan||CPM||Chemotherapy - Alkylating 16||Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).|
|Fludarabine||Fludara||FAMP|Fludarabine phosphate||Flurdara (fludarabine) is converted to 2-fluoro-ara-ATP intracellularly, which potentially inhibits DNA polymerase alpha, ribonucleotide reductase and DNA primase, leading to decreased DNA synthesis and reduced tumor growth (NCI Drug Dictionary)|
|TAC01-HER2||TAC 01-HER2|TAC-01-HER2|TAC-engineered T Cells TAC01-HER2||TAC01-HER2 are autologous T-lymphocytes engineered to express an ERBB2 (HER2) T-Cell Antigen-Coupler (TAC), which leads to activation and targeting of T-lymphocytes to ERBB2 (HER2)-positive tumor cells, potentially resulting in inhibition of tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr CT247).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04727151||Phase Ib/II||Cyclophosphamide + Fludarabine + TAC01-HER2||TAC T-cells for the Treatment of HER2-positive Solid Tumors (TACTIC-2)||Recruiting||USA | CAN||0|